Hospital-Acquired Anemia: Epidemiology, Prevention and Management in Patients with Acute Coronary Syndromes
|
|
- Hortense Ross
- 5 years ago
- Views:
Transcription
1 Hospital-Acquired Anemia: Epidemiology, Prevention and Management in Patients with Acute Coronary Syndromes Adam C. Salisbury, MD, MSc January 23, 2012
2 Case 64 year old woman with no cardiac history, medical history of hypertension, type II diabetes Presents Friday night to her local ED sudden substernal chest pain, EKG shows anterolateral ST depression Symptoms resolve with nitroglycerin, metoprolol Started on aspirin, clopidogrel and heparin Transferred to Saint Luke s Hospital Baseline hemoglobin 12.4 g/dl, admit creatinine 1.5 mg/dl
3 Clinical Scenario Remains pain free, admission EKG shows resolution of her ST segment changes Managed medically over the weekend Coronary angiography Monday Pre-procedure : Hgb 11.0 g/dl, creatinine % mid-distal LAD lesion stented with a single drug-eluting stent Manual compression for sheath pull; small hematoma Discharged home next day Hgb 10.7 g/dl
4 Hospital-Acquired Anemia (HAA) Not an uncommon scenario normal admission hemoglobin, anemic at discharge How frequent at the time of acute coronary syndrome (ACS)? Is this important? Poor outcomes? What can/should we do about HAA?
5 Chronic Anemia & Outcomes After Acute Coronary Syndromes Chronic anemia associated with poorer survival and worse health status acute coronary syndrome patients
6 Sabatine et al. Circulation. 2005;111:
7 Anker et al. Eur Heart J. 2009(30):
8 Anemia and Mortality Decreased blood oxygen carrying capacity Promote arrhythmia Exacerbate myocardial ischemia Increase sympathetic tone Exacerbate shock in setting of compromised ventricular function Levy, et al. Am J Physiol. 1993;265:H Levy, et al. J Trauma. 1996;41:
9 Chronic Anemia & Outcomes After Acute Coronary Syndromes Is it actionable? Challenges in addressing chronic anemia Complex interplay of underlying illness and inflammation No opportunity for prevention Treatments - disappointing results Transfusion benefit transient and may increase mortality Erythropoietin stimulating agents augment hemoglobin but increase risk for stroke and thromboembolic events
10 Hospital-Acquired Anemia (HAA) New anemia in patients with normal admission hemoglobin Common at the time of acute coronary syndromes Associated with greater mortality Worse physical functioning Commonly persistent in recovery after ACS Salisbury, et. al. Circ Cardiovasc Qual Outcomes; 2010: 3(4): Salisbury, et. al. Am J Cardiol; 2011: 108(7): Salisbury, et. al. Am Heart J; 2011: 162(2): e3
11 HAA is Common Without HAA 55% With HAA 45% Mod- Severe 26% Mild 74% Salisbury, et. al. Circ Cardiovasc Qual Outcomes; 2010: 3(4):
12 HAA is Associated with Poor Outcomes 12 month mortality HR (95% CI) Multivariable Adjusted Hospital acquired: mild Hospital acquired: moderate/severe Chronic Anemia 1.20 (0.75, 1.90) 1.82 (1.11, 2.98) 2.31 (1.57, 3.40) <<Lower Mortality Risk Higher Mortality Risk>> Salisbury, et al. Circ Cardiovasc Qual Outcomes; 2010: 3(4):
13 Salisbury, et al. Am J Cardiol. 2011; 162(2): e3.
14 Why is HAA Important? HAA is often persistent in follow-up Persistent 31% Resolved 69% Persistence is associated with worse health status Salisbury, et al. Am J Cardiol; 2011: 108(7):
15 SF-12 PCS Scores Across Follow-up Points (95% CI) Unadjusted Persistent vs. Resolved (-3.71, -0.55) Multivariable Adjusted Persistent vs. Resolved (-3.95, -0.84) Salisbury, et al. Am J Cardiol; 2011: 108(7):
16 Why is HAA Important? In contrast to chronic anemia, may be preventable Related to processes of care Peri-procedural bleeding Other modifiable risk factors?
17 HAA Incidence Across TRIUMPH Hospitals % 90.00% 80.00% 70.00% Range 33.3% to 69.2% Median rate ratio for hospital site: 1.13 (95% CI ) 60.00% 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% Hospital Salisbury, et al. Circ Cardiovasc Qual Outcomes; 2010: 3(4):
18 HAA commonly occurs in the absence of bleeding Without In-Hospital Bleeding 87% Inpatient Bleeding 13% Even in pts with severe HAA 48% had no documented bleeding Salisbury, et al. Circ Cardiovasc Qual Outcomes; 2010: 3(4):
19 Potentially Modifiable Risk Factors Bleeding Phlebotomy Unrecognized Iron Deficiency HAA Non-Modifiable Risk Factors Age Gender Underlying comorbidities (i.e. renal disease, heart failure) Acute inflammation from myocardial necrosis Hemodilution
20 Diagnostic Blood Loss From Phlebotomy and HAA HAA commonly develops in the absence of recognized bleeding Could phlebotomy be a risk factor for HAA? Small studies in non-cardiac populations More blood transfusions, in-hospital Hgb declines No studies had tested the relationship between diagnostic blood loss and HAA in AMI patients Thavendiranathan P, et al. J Gen Intern Med. 2005; 20(6): Chant C.Crit Care. 2006; 10(5):R140.
21 Cerner Health Facts Health Facts captured de-identified data of consecutive AMI hospitalizations Detailed demographic and comorbidity data as well as all in-hospital labs, medications, procedures, complications Date & time of all labs drawn and tests ordered with each draw known for all patients
22 AMI Dx, elevated biomarkers, > 24 hour stay, only 1 st AMI N=38,422 n=37,892 Transfers from other hospitals (n=81), from hospital enrolling < 20 pts (n=57), LOS > 31 days (n=392) CABG during admission (n=3,990) n=33,902 n=28,100 No Hgb 1 st 24 hrs (n=2,225), Fewer than 2 Hgb values (n=3,577) Anemic on admit Hgb N = 17,676 (from 57 hospitals) with AMI & no anemia at admission (n=10,424)
23 Anemia Definition Age, gender and race specific more accurate than WHO Beutler and Waalen Anemia Definition (g/dl) Male <60 Male 60 Female Caucasian Non-Caucasian Beutler and Waalen. Blood. 2006;107(5):
24 HAA Severity Definitions Mild - Hgb > 11.0 g/dl Moderate-Severe - Hgb 11.0 g/dl Only moderate-severe HAA associated with poor outcomes Used as outcome of present study Salisbury, et. al. Circ Cardiovasc Qual Outcomes; 2010: 3(4):
25 Blood Loss from Phlebotomy Date/time of all phlebotomy events known Based upon tests obtained, types of tubes needed to run labs identified Conservative assumptions - assumed a single tube of each type per phlebotomy event Did not account for wasted blood volume # and type of tubes multiplied by standard volumes for each type of tube based on prior literature
26 Blood Volumes Per Tube Chemistries 5 ml CBCs (EDTA tube) 5 ml Coagulation Studies (citrate) 4.5 ml ABGs 2 ml Blood cultures 10 ml per culture Chant C.Crit Care. 2006; 10(5):R140.
27 Between Hospital Variability Mean estimated diagnostic blood loss from phlebotomy over course of hospitalization at each Health Facts hospital Shrinkage estimates to account for smaller enrollments
28 Statistical Analyses Multivariable Poisson regression with robust error variance Adjusted for potential confounders based upon clinical experience and prior literature Zou, G. Am J Epidemiol. 2004;159(7):
29 Incidence of Moderate-Severe HAA 20.1% 3551 patients (20.1%) developed moderatesevere HAA 79.9% Salisbury, et al. Arch Intern Med; 171(18):
30 Patient Characteristics Moderate-severe HAA (n=3,551) Mild HAA or No HAA (n=14,125) p-value Age (mean±sd) 71.9 ± ± 14.5 < Gender (% female) 2481 (69.9%) 4651 (32.9%) < Race (% Caucasian) 2933 (82.6%) (87.2%) < Heart failure 1377 (38.8%) 2995 (21.2%) < Chronic kidney disease 454 (12.8%) 648 (4.6%) < Diabetes 1134 (31.9%) 3566 (25.2%) < Cardiogenic shock 336 (9.5%) 305 (2.2%) < In hospital mechanical ventilation 390 (11.0%) 422 (3.0%) < Length of stay (Median (IQR)) 6.5 (4.1, 10.1) 3.5 (2.5, 5.0) < 0.001
31 Diagnostic Blood Loss Diagnostic Blood Loss (ml) % 173.8of patients p<0.001 with moderatesevere HAA had > 300 ml drawn 3.8% > 500 ml of blood drawn Moderate-severe HAA No Moderate-severe HAA Salisbury, et al. Arch Intern Med; 171(18):
32 Shrinkage Estimates of Diagnostic Blood Loss Across Hospitals Total diagnostic blood loss (ml) Moderate-severe HAA No Moderate-severe HAA Moderate-severe HAA: range ml Mild HAA or No HAA: range ml Hospital
33 Multivariable Model Variable RR Lower CI Upper CI p-value Diagnostic blood loss <.0001 (per 50 ml) Age (10 year increase) <.0001 Female <.0001 Non-Caucasian <.0001 ST elevation MI Acute Renal Failure Heparin Cardiogenic Shock In hospital Cath or PCI Glycoprotein IIb/IIIa <0.001 inhibitor Bivalirudin Antiplatelet Beta-Blocker Statin ACE/ARB Aspirin Thrombolytics Mechanical ventilation <.0001 CKD <.0001 Prior MI Diabetes Heart failure Hypertension <.0001 Adjusted for a broad spectrum of potential confounders: Each 50 ml of diagnostic blood loss associated with a 15% increase in the risk of moderate-severe HAA
34 Potential Impact of Pediatric Tubes Low volume pediatric tubes require no changes in clinical practice of ordering diagnostic tests, little change in cost to hospitals Compared with the primary analyses 64% reduction in mean blood loss in moderatesevere group 68% reduction in mean blood loss in other pts Salisbury, et al. Arch Intern Med; 171(18):
35 Reducing Diagnostic Blood Loss Widespread use of pediatric tubes Little to no extra cost to hospitals, often compatible with existing equipment Important reductions in diagnostic blood loss without changes in physician behavior Increasing use of stored serum samples Routinely batching lab draws Eliminating unnecessary scheduled phlebotomy
36 Hematologic/Iron Deficiency Evaluation 100% % with moderate-severe HAA 90% 80% 70% 60% 50% 40% 30% 20% 10% 18.3% 28.0% p< % 45.5% 0% Normal RDW & MCV Normal RDW & low MCV Elevated RDW & normal MCV Elevated RDW & low MCV Salisbury, et al. Am J Cardiol. 2012; 109(1):13-18.
37 Periprocedural Bleeding Avoidance Variety of catheterization lab strategies have been advocated
38 Current Study Pilot project Implementing common sense measures to reduce diagnostic phlebotomy volumes 800 patients 400 pre, 400 post intervention Multidisciplinary team Process of care changes
39 As part of the Hospital Acquired Anemia study you are involved in use 2ml Tubes (Pedi Tubes) for lab draws Smaller tube volume (2ml) White ring = Pediatric tube Routine microdraws for ABG (<1 ml) Place sign above patient s bed and magnet on door frame for communication to phlebotomist
40 As part of the Hospital Acquired Anemia (HAA) study you are involved in please use the new reinfusion kit for all of your central line draws
41 As part of the Hospital Acquired Anemia (HAA) study you are involved in please use the SIL process for lab draws whenever possible Automatic SIL labs, unless specified by MD
42 As part of the Hospital Acquired Anemia (HAA) study you are involved in routine labs will now batch All routine labs batched 0830, 1430, and 2300 Draw and result times are approximate Timed and Stat lab orders: no changes 0830 Batching Time 0900 Labels print, phlebotomist to draw 1130 Results available 1430 Batching Time 1500 Labels print, phlebotomist to draw 1730 Results available 2300 Batching Time: same as current practice
43 As part of the Hospital Acquired Anemia (HAA) study you are involved in you may see In addition to the previous interventions you may see this sticker on the outside of your patient s chart. This sticker is to communicate to the physician that your patient is at high risk for anemia and to consider limiting blood draws. Monthly resident education sessions to reinforce judicious blood draw practices
44 Conclusions HAA is common at the time of acute coronary syndromes HAA portends a poor prognosis May be preventable by changing processes of in-hospital care Future directions Impact of phlebotomy reduction on outcomes Role of iron deficiency screening, hematologic evaluation Combined approach including bleeding prevention measures in the CV lab for high risk patients
45 Thank you! Contact information: Adam Salisbury, MD, MSc Saint Luke s Mid America Heart Institute 4401 Wornall Road, Kansas City, MO Phone: Fax: salisbury.adam@yahoo.com
ASSOCIATION OF DIAGNOSTIC BLOOD LOSS FROM PHLEBOTOMY AND HOSPITAL- ACQUIRED ANEMIA DURING ADMISSION WITH ACUTE MYOCARDIAL INFARCTION C2010
ASSOCIATION OF DIAGNOSTIC BLOOD LOSS FROM PHLEBOTOMY AND HOSPITAL- ACQUIRED ANEMIA DURING ADMISSION WITH ACUTE MYOCARDIAL INFARCTION By C2010 Adam C. Salisbury BA, University of Missouri-Kansas City, 2006
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationVersion 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM
Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute
More informationOvercoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationNew Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)
A. ADMINISTRATIVE New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.) 1. Facility Code: 2. Facility Name: 3. Procedure Type (Choose only
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationNCDR CathPCI Registry v4.4 Diagnostic Catheterization and Percutaneous Coronary Intervention Registry
A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - - SSN N/A 2031 Patient ID 2040 : (auto) Other ID 2045 : Birth Date 2050 : *** @ Sex 2060 : *** @ O Male O Female Race:
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationDaily practice of ACS management in the Gulf: Data from Gulf COAST
Daily practice of ACS management in the Gulf: Data from Gulf COAST Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Head, Division of Cardiology Mubarak Alkabeer Hospital
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationDecrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs
Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs (family hotel, drive back to the VA for next day pick up)
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationCoronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study
Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationOccurrence of Bleeding and Thrombosis during Antiplatelet therapy In Non-cardiac surgery. A prospective observational study.
Occurrence of Bleeding and Thrombosis during Antiplatelet therapy In Non-cardiac surgery A prospective observational study OBTAIN Study Statistical Analysis Plan of Final Analysis Final Version: V1.1 from
More informationHot Topics in Cardiac Arrest. Should the patient go To the Cath Lab?
Hot Topics in Cardiac Arrest Should the patient go To the Cath Lab? Tim Russert 1950-2008 Host of NBC s Meet the Press Sudden Cardiac Arrest : Autopsy showed plaque rupture in his LAD ( per LA Times,
More informationSTEMI, Non-STEMI, Chest Pain?
Minnesota Chest Pain / Acute Coronary Syndrome Tool-Kit Patient with Chest Pain Or Potential Acute Coronary Syndrome STEMI, n-stemi, Chest Pain? Follow MN STEMI Guideline Follow MN n-stemi Guideline Follow
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationDownloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
More informationTransfusion for the sickest ICU patients: Are there unanswered questions?
Transfusion for the sickest ICU patients: Are there unanswered questions? Tim Walsh Professor of Critical Care Edinburgh University None Conflict of Interest Guidelines on the management of anaemia and
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationPeri-Surgical Anemia and the TAVR Patient
Peri-Surgical Anemia and the TAVR Patient Kathrine P Frey, MD Fairview Southdale Hospital Director of Blood and Pre-Operative Anemia Management April, 2015 MIDWEST VALVE SYMPOSIUM, April 2015 Credentials
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationDECLARATION OF CONFLICT OF INTEREST. None declared
DECLARATION OF CONFLICT OF INTEREST None declared Coronary Artery Disease, Aspirin, and Perioperative Myocardial Infarction and Bleeding in Orthopedic Surgery Brandon Oberweis, MD*, Swetha Nukala, MBBS*,
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationHIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD
HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting honorariums or other payments
More informationClinical Lessons from BMC2-PCI
Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More information2. If prasugrel is found to be both more costly and more effective than clopidogrel, to assess its costeffectiveness
Cost-Effectiveness of Prasugrel vs. Clopidogrel for PCI Patients with Acute Coronary Syndromes: Results from the TRITON-TIMI TIMI 38 Trial David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationManagement of new-onset AF: Initial rate control treatment
Geneva Acute Crdiovascular Care Congress 2014 - October 18-20, 2014 Management of new-onset AF: Initial rate control treatment Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation,
More informationDiagnosis and Management of Acute Myocardial Infarction
Diagnosis and Management of Acute Myocardial Infarction Acute Myocardial Infarction (AMI) occurs as a result of prolonged myocardial ischemia Atherosclerosis leads to endothelial rupture or erosion that
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationSHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?
SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
More informationWilliam D. Salerno, M.D. Director, Coronary Care Unit Hackensack University Medical Center Clinical Associate Professor of Medicine, UMDNJ
William D. Salerno, M.D. Director, Coronary Care Unit Hackensack University Medical Center Clinical Associate Professor of Medicine, UMDNJ PROBLEM: blood supply to the heart has been compromised and heart
More informationPERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW
PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW Bruce Biccard Perioperative Research Group, Department of Anaesthetics 18 June 2015 Disclosure Research funding received Medical Research
More informationData Elements and Definitions with Case Studies. Interpreting Your Outcomes Reports. Kim Hustler, Clinical Quality Consultant, NCDR
Data Elements and Definitions with Case Studies Interpreting Your Outcomes Reports Kim Hustler, Clinical Quality Consultant, NCDR Beth Pruski, Program Manager, NCDR The following relationships exist: Beth
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationAcute Coronary Syndrome
Acute Coronary Syndrome Clinical Manifestation of CAD Silent Ischemia/asymptomatic Stable Angina Acute Coronary Syndrome (Non- STEMI/UA and STEMI) Arrhythmias Heart Failure Sudden Death Pain patterns with
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS EPTIFIBATIDE (INTEGRILIN) PROTOCOL
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE S EPTIFIBATIDE (INTEGRILIN) I. PURPOSE: A. Integrilin (Eptifibatide) is a specific and potent inhibitor of the platelet receptor glycoprotein
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More information2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics
NCDR.13 Case Scenario Presentation Cath PCI Registry Dashboard Implications of Some Major Metrics Disclosures Tony Hermann has nothing to disclose Mark Hutcheson has nothing to disclose Cornelia Anderson
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationCardiothoracic Department October 9, Deborah Winters, RN BSN Clinical Excellence
Cardiothoracic Department October 9, 2013 Deborah Winters, RN BSN Clinical Excellence Quarterly Executive Summary CathPCI Registry PCI Performance Measures PCI Process/Outcome Metrics Diagnostic Cath Process/Outcome
More informationPre Hospital and Initial Management of Acute Coronary Syndrome
Pre Hospital and Initial Management of Acute Coronary Syndrome Dr. Muhammad Fadil, SpJP 3rd SymCARD 2013 Classification of ACS ESC Guidelines for the management of Acute Coronary Syndrome in patients without
More informationClinical Controversies in Perioperative Medicine
Update on Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Medications & Perioperative
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationPhysician Orders ADULT: PCI Post Procedure Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase Phase: PCI Post Procedure Phase, When to Initiate: Initiate Powerplan Phase Phase: Post Cath/PCI Hydration Protocol Phase,
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationUtilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationWomen and Ischemic Heart Disease Lessons Learned
Women and Ischemic Heart Disease 2017- Lessons Learned Bina Ahmed MD Interventional Cardiology Dartmouth-Hitchcock Medical Center Assistant Professor of Medicine Geisel School of Medicine Lebanon, NH ba@hitchcock.org
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More information2010 ACLS Guidelines. Primary goals of therapy for patients
2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationDR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI
The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More information1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11
May 2011 1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11 Yes b) If confirmed please provide details on the number of
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More information